Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stake Boosted by Swiss National Bank
Swiss National Bank increased its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 2.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 150,200 shares of the company’s stock after acquiring an additional 2,900 shares during the period. Swiss National Bank owned about 0.17% of Neurocrine Biosciences worth $11,654,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also recently made changes to their positions in NBIX. Northern Trust Corp raised its holdings in shares of Neurocrine Biosciences by 0.8% during the second quarter. Northern Trust Corp now owns 475,963 shares of the company’s stock worth $21,894,000 after acquiring an additional 3,887 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Neurocrine Biosciences by 6.5% during the second quarter. Dimensional Fund Advisors LP now owns 176,197 shares of the company’s stock worth $8,105,000 after acquiring an additional 10,782 shares in the last quarter. Cubist Systematic Strategies LLC raised its holdings in shares of Neurocrine Biosciences by 151.5% during the second quarter. Cubist Systematic Strategies LLC now owns 5,301 shares of the company’s stock worth $244,000 after acquiring an additional 3,193 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of Neurocrine Biosciences by 7.8% during the second quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock worth $123,000 after acquiring an additional 193 shares in the last quarter. Finally, Quantitative Systematic Strategies LLC purchased a new stake in shares of Neurocrine Biosciences during the third quarter worth $305,000.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) opened at $91.73 on Friday. Neurocrine Biosciences, Inc. has a 1-year low of $39.21 and a 1-year high of $92.98. The company has a current ratio of 10.20, a quick ratio of 10.20 and a debt-to-equity ratio of 0.99. The firm has a market capitalization of $8,066.76, a PE ratio of -55.93 and a beta of 0.31.
Several brokerages recently issued reports on NBIX. Barclays reiterated an “overweight” rating and set a $100.00 price objective on shares of Neurocrine Biosciences in a report on Wednesday, February 14th. Piper Jaffray Companies reiterated an “overweight” rating and set a $113.00 price objective on shares of Neurocrine Biosciences in a report on Wednesday. BidaskClub upgraded Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a report on Wednesday, January 31st. Jefferies Group increased their price objective on Neurocrine Biosciences to $105.00 and gave the stock a “buy” rating in a report on Friday, January 5th. Finally, Oppenheimer set a $85.00 price objective on Neurocrine Biosciences and gave the stock a “buy” rating in a report on Tuesday, December 12th. One investment analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. Neurocrine Biosciences has an average rating of “Buy” and a consensus price target of $95.23.
In other news, insider Haig P. Bozigian sold 75,873 shares of Neurocrine Biosciences stock in a transaction dated Monday, March 5th. The stock was sold at an average price of $90.00, for a total value of $6,828,570.00. Following the transaction, the insider now directly owns 18,041 shares in the company, valued at $1,623,690. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Darin Lippoldt sold 15,237 shares of Neurocrine Biosciences stock in a transaction dated Thursday, December 28th. The stock was sold at an average price of $75.00, for a total value of $1,142,775.00. Following the completion of the transaction, the insider now owns 28,394 shares in the company, valued at $2,129,550. The disclosure for this sale can be found here. Insiders sold 399,589 shares of company stock worth $32,443,795 over the last quarter. 4.80% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by Marea Informative and is owned by of Marea Informative. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.mareainformativa.com/2018/03/16/swiss-national-bank-has-11-65-million-stake-in-neurocrine-biosciences-inc-nbix-updated-updated-updated.html.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.